scispace - formally typeset
J

Jessica M. Clement

Researcher at University of Connecticut Health Center

Publications -  31
Citations -  1658

Jessica M. Clement is an academic researcher from University of Connecticut Health Center. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 9, co-authored 28 publications receiving 1029 citations. Previous affiliations of Jessica M. Clement include University of Connecticut & Beth Israel Deaconess Medical Center.

Papers
More filters
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.

TL;DR: A phase II trial is discussed that investigates predictive biomarkers that might help clinicians identify the patient population with metastatic RCC that would benefit from IL-2 therapy and therefore limit patients who receive this toxic therapy to those most likely to benefit.
Journal ArticleDOI

Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer:

TL;DR: A potential opportunity exists to maximize oral chemotherapy treatment outcomes with the addition of a formalized monitoring program directed by an oncology pharmacist.
Journal ArticleDOI

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.

Maheen Z. Abidi, +282 more
- 14 Dec 2020 - 
TL;DR: Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.